資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/122706
|
| 題名: | Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy |
| 作者: | Huang, Sung-Hsi;Lin, Shu-Wen;Chang, Sui-Yuan;Lin, Ya-Ting;Chiang, Chieh;Hsiao, Chin-Fu;Sun, Hsin-Yun;Liu, Wen-Chun;Su, Yi-Ching;Hung, Chien-Ching;Chang, Shan-Chwen |
| 日期: | 2017-11-23 |
| 上傳時間: | 2022-05-09 12:10:45 (UTC+8) |
| 摘要: | We investigated the predictors of plasma mid-dose concentrations (C12) of efavirenz by enrolling 456 HIV-positive patients who had received 2 nucleos(t)ide reverse-transcriptase inhibitors plus efavirenz (600 mg daily) for 2 weeks or longer and had their CYP2B6 516G>T polymorphism and efavirenz C12 determined. The median efavirenz C12 was 2.41 mg/L (IQR, 1.93–3.14). In analysis of covariance models, patients with CYP2B6 516GT and TT genotypes compared to those with GG genotype had higher efavirenz C12 (for GT genotype, an increase by 0.976 mg/L [95%CI, 0.765–1.188], and TT genotype, 4.871 mg/L [95%CI, 4.126–5.616]), while per 10-kg increment in weight decreased C12 by 0.199 mg/L (95%CI, 0.111–0.287). Models incorporating CYP2B6 516G>T polymorphism and weight had moderate predictive values in predicting efavirenz C12 ≥ 2 mg/L (ROC area under curve = 0.706 [95%CI, 0.656–0.756]). In the absence of CYP2B6 516G>T polymorphism, weight ≤58 kg provided better predictabilities for efavirenz C12 ≥ 2 mg/L (probability, 77.1% [95%CI, 69.0–83.5%] for weight = 50 kg and 70.6% [95%CI, 64.1–76.4%] for weight = 58 kg). |
| 關聯: | Scientific reports 7(1), 16187 |
| DOI: | 10.1038/s41598-017-16483-2 |
| 顯示於類別: | [數學學系暨研究所] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 23 | 檢視/開啟 |
|
在機構典藏中所有的資料項目都受到原著作權保護.
|
